FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.8.4  |  FHIR Version n/a  User: [n/a]

1495581000168106: List of Medicines for Brand Consideration reference set (foundation metadata concept)


Status: current, Primitive. Date: 30-Sep 2020. Module: Third party reference set module

Descriptions:

Id Description Lang Type Status Case? Module
4462321000168116 List of Medicines for Brand Consideration reference set (foundation metadata concept) en Fully specified name Active Initial character case insensitive Third party reference set module
4462331000168118 List of Medicines for Brand Consideration reference set en Synonym Active Initial character case insensitive Third party reference set module
4462411000168119 List of Medicines for Brand Consideration (LMBC) reference set en Synonym Active Initial character case insensitive Third party reference set module
4462641000168118 <p>Supports the identification of AMT Medicinal Product Unit of Use (MPUU) and Medicinal Product Pack (MPP) concepts associated with the List of Medicines for Brand Consideration (LMBC) that forms part of the Active Ingredient Prescribing initiative. Under the <i>National Health (Pharmaceutical Benefits) Regulations 2017</i>, the <i>Repatriation Pharmaceutical Benefits Scheme Instrument 2013</i> and <i>MRCA Pharmaceutical Benefits Scheme Instrument 2013</i>, all PBS and RPBS prescriptions must be prepared by active ingredient, the brand may additionally be identified if a prescriber considers it necessary. The LMBC supports prescribers' decision-making regarding the inclusion of brand on a prescription.</p><p>This reference set can be used by prescribing software vendors to identify medications for brand consideration to meet Active Ingredient Prescribing requirements.</p><p><b>Target Client:&nbsp;</b>This reference set was developed by the National Clinical Terminology Service for the Australian Government Department of Health and Aged Care to support the Active Ingredient Prescribing initiative, and can be used by developers to assist with the requirements.</p> en Definition Active Case sensitive Third party reference set module


1324 members. Search Members:

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
List of Medicines for Brand Consideration reference set Is a Reference sets for Medications true Inferred relationship Some
List of Medicines for Brand Consideration reference set Is a Simple type reference set true Inferred relationship Some
List of Medicines for Brand Consideration reference set Developed by Australian Government Department of Health and Aged Care true Inferred relationship Some 1570063879

Members
oxycodone hydrochloride 20 mg capsule
oxycodone hydrochloride 20 mg capsule, 10
oxycodone hydrochloride 20 mg capsule, 20
oxycodone hydrochloride 20 mg capsule, 60
oxycodone hydrochloride 20 mg modified release tablet
oxycodone hydrochloride 20 mg modified release tablet, 10
oxycodone hydrochloride 20 mg modified release tablet, 100
oxycodone hydrochloride 20 mg modified release tablet, 120
oxycodone hydrochloride 20 mg modified release tablet, 20
oxycodone hydrochloride 20 mg modified release tablet, 28
oxycodone hydrochloride 20 mg modified release tablet, 60
oxycodone hydrochloride 5 mg tablet
oxycodone hydrochloride 5 mg tablet, 10
oxycodone hydrochloride 5 mg tablet, 20
oxycodone hydrochloride 5 mg tablet, 500
oxycodone hydrochloride 5 mg tablet, 6
oxycodone hydrochloride 5 mg tablet, 8
paclitaxel (as nanoparticle albumin-bound) 100 mg injection, 1 vial
paclitaxel (as nanoparticle albumin-bound) 100 mg injection, vial
paclitaxel (as nanoparticle albumin-bound) 250 mg injection, 1 vial
paclitaxel (as nanoparticle albumin-bound) 250 mg injection, vial
paliperidone 100 mg modified release injection, 1 syringe
paliperidone 100 mg modified release injection, syringe
paliperidone 150 mg modified release injection, 1 syringe
paliperidone 150 mg modified release injection, syringe
paliperidone 175 mg/0.875 mL modified release injection, syringe
paliperidone 175 mg/0.875 mL modified release injection, 0.875 mL syringe
paliperidone 25 mg modified release injection, 1 syringe
paliperidone 25 mg modified release injection, syringe
paliperidone 263 mg/1.315 mL modified release injection, 1.315 mL syringe
paliperidone 263 mg/1.315 mL modified release injection, syringe
paliperidone 350 mg/1.75 mL modified release injection, 1.75 mL syringe
paliperidone 350 mg/1.75 mL modified release injection, syringe
paliperidone 50 mg modified release injection, 1 syringe
paliperidone 50 mg modified release injection, syringe
paliperidone 525 mg/2.625 mL modified release injection, 2.625 mL syringe
paliperidone 525 mg/2.625 mL modified release injection, syringe
paliperidone 75 mg modified release injection, 1 syringe
paliperidone 75 mg modified release injection, syringe
peginterferon alfa-2a 135 microgram/0.5 mL injection [4 x 0.5 mL syringes] (&) ribavirin 200 mg tablet [112], 1 pack
peginterferon alfa-2a 135 microgram/0.5 mL injection [4 x 0.5 mL syringes] (&) ribavirin 200 mg tablet [140], 1 pack
peginterferon alfa-2a 135 microgram/0.5 mL injection [4 x 0.5 mL syringes] (&) ribavirin 200 mg tablet [168], 1 pack
peginterferon alfa-2a 135 microgram/0.5 mL injection [4 x 0.5 mL syringes] (&) ribavirin 200 mg tablet [84], 1 pack
peginterferon alfa-2a 135 microgram/0.5 mL injection, syringe
peginterferon alfa-2a 135 microgram/0.5 mL injection, 4 x 0.5 mL syringes
peginterferon alfa-2a 180 microgram/0.5 mL injection [4 x 0.5 mL syringes] (&) ribavirin 200 mg tablet [112], 1 pack
peginterferon alfa-2a 180 microgram/0.5 mL injection [4 x 0.5 mL syringes] (&) ribavirin 200 mg tablet [140], 1 pack
peginterferon alfa-2a 180 microgram/0.5 mL injection [4 x 0.5 mL syringes] (&) ribavirin 200 mg tablet [168], 1 pack
peginterferon alfa-2a 180 microgram/0.5 mL injection [4 x 0.5 mL syringes] (&) ribavirin 200 mg tablet [84], 1 pack
peginterferon alfa-2a 180 microgram/0.5 mL injection, syringe
peginterferon alfa-2a 180 microgram/0.5 mL injection, 4 x 0.5 mL syringes
peginterferon beta-1a 125 microgram/0.5 mL injection, syringe
peginterferon beta-1a 125 microgram/0.5 mL injection, 2 x 0.5 mL syringes
peginterferon beta-1a 63 microgram/0.5 mL injection [0.5 mL pen device] (&) peginterferon beta-1a 94 microgram/0.5 mL injection [0.5 mL pen device], 1 pack
peginterferon beta-1a 63 microgram / 0.5 mL injection [1 x 0.5 mL syringe] (&) peginterferon beta-1a 94 microgram / 0.5 mL injection [1 x 0.5 mL syringe], 1 pack (medicinal product pack)
peginterferon beta-1a 63 microgram / 0.5 mL injection, 0.5 mL pen device (medicinal product unit of use)
peginterferon beta-1a 63 microgram/0.5 mL injection, syringe
peginterferon beta-1a 63 microgram/0.5 mL injection, 0.5 mL pen device
peginterferon beta-1a 63 microgram/0.5 mL injection, 0.5 mL syringe
peginterferon beta-1a 94 microgram/0.5 mL injection, pen device
peginterferon beta-1a 94 microgram/0.5 mL injection, syringe
peginterferon beta-1a 94 microgram/0.5 mL injection, 0.5 mL pen device
peginterferon beta-1a 94 microgram/0.5 mL injection, 0.5 mL syringe
primidone 250 mg tablet
primidone 250 mg tablet, 100
primidone 250 mg tablet, 200
progesterone 100 mg pessary
progesterone 100 mg pessary, 15
progesterone 100 mg pessary, 21
progesterone 100 mg pessary, 30
progesterone 100 mg pessary, 5
progesterone 200 mg pessary
progesterone 200 mg pessary, 14
progesterone 200 mg pessary, 15
progesterone 200 mg pessary, 21
progesterone 200 mg pessary, 28
progesterone 200 mg pessary, 30
progesterone 200 mg pessary, 42
progesterone 200 mg pessary, 45
progesterone 200 mg pessary, 5
progesterone 200 mg pessary, 56
progesterone 200 mg pessary, 7
progesterone 200 mg pessary, 84
progesterone 200 mg pessary, 90
quinine bisulfate heptahydrate 300 mg tablet
quinine bisulfate heptahydrate 300 mg tablet, 50
quinine sulfate dihydrate 300 mg tablet
quinine sulfate dihydrate 300 mg tablet, 50
salbutamol 100 microgram/actuation inhalation, 100 actuations
salbutamol 100 microgram / 1 actuation inhalation, 200 actuations (medicinal product pack)
salbutamol 100 microgram / 1 actuation inhalation, actuation (medicinal product unit of use)
somatrogon 24 mg/1.2 mL injection, 1.2 mL pen device
somatrogon 24 mg/1.2 mL injection, pen device
somatropin 1 mg injection, chamber
somatropin 1.2 mg injection, chamber
somatropin 1.4 mg injection, chamber
somatropin 1.6 mg injection, chamber
somatropin 1.8 mg injection, chamber
somatropin 10 mg/1.5 mL injection
somatropin 10 mg/1.5 mL injection, 1.5 mL cartridge
somatropin 10 mg/1.5 mL injection, 1.5 mL

Start Previous Page 12 of 14 Next End


Reference Sets

Australian dialect reference set

Reference set descriptor

Back to Start